Tolerability of 5 mg Solifenacin Once Daily Versus 5 mg Oxybutynin Immediate Release 3 Times Daily: Results of the VECTOR Trial

Journal of Urology

Volumn 183, Issue 5, 2010, Pages 1892-1898

  Herschorn, Sender ^a   Stothers, Lynn ^e   Carlson, Kevin ^g   Egerdie, Blair ^c   Gajewski, Jerzy B ⁱ   Pommerville, Peter ^f   Schulz, Jane ^h   Radomski, Sidney ^a   Drutz, Harold ^b   Barkin, Jack ^b   Paradiso Hardy, Fran ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Urology Associates/Urologic Medical Research   (Canada)

^d Astellas Pharma Canada Inc   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Can Med Clinical Research Inc   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Canada; overactive; oxybutynin; quinuclidin 3' yl 1 phenyl 1,2,3,4 tetrahydroisoquinoline 2 carboxylate monosuccinate; urinary bladder; xerostomia

Indexed keywords

OXYBUTYNIN; PLACEBO; SOLIFENACIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NOCTURIA; OVERACTIVE BLADDER; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; URINARY FREQUENCY; URINARY URGENCY; URINE VOLUME; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; CANADA; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUESTIONNAIRES; QUINUCLIDINES; SEVERITY OF ILLNESS INDEX; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; XEROSTOMIA;

EID: 77950471275     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.01.012     Document Type: Article

References (27)

1. Herschorn S., Gajewski J., Schulz J., et al. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU Int 101 (2008) 52
2. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 (2006) 1306
3. Brown J.S., McGhan W.F., and Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 6 (2000) S574
4. Chancellor M.B. New frontiers in the treatment of overactive bladder and incontinence. Rev Urol 4 suppl. (2002) S50
5. Noe L., Sneeringer R., Patel B., et al. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface 17 (2004) 54
6. D'Souza A.O., Smith M.J., Miller L.A., et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharmacol 14 (2008) 291
7. Chapple C., Khullar V., Gabriel Z., et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48 (2005) 5
8. Abrams P., Freeman R., Anderström C., et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81 (1998) 801
9. ® (oxybutynin chloride) (2008), Ortho-McNeil Pharmaceuticals Inc, Kansas City. https://www.ortho-mcneilpharmaceutical.com/ortho-mcneilpharmaceutical/shared/pi/Lg%20Ditropan%20PI.pdf#zoom=100 Accessed August 10, 2009
10. Ohtake A., Ukai M., Hatanaka T., et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 492 (2004) 243
11. VESIcare (2008), Astellas Pharma US Inc, Deerfield, Illinois. http://www.astellas.us/docs/vesicare.pdf Accessed August 10, 2009
12. Guideline for Good Clinical Practice. ICH Harmonised Tripartite Guideline. European Medicines Agency. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed August 10, 2009
13. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. World Medical Association. http://www.wma.net/e/policy/b3.htm Accessed August 10, 2009
14. Versi E., Appell R., Mobley D., et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 95 (2000) 718
15. Coyne K.S., Matza L.S., Kopp Z., et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49 (2006) 1079
16. Coyne K., Revicki D., Hunt T., et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11 (2002) 563
17. Homma Y., Paick J.S., Lee J.G., et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 92 (2003) 741
18. Cardozo L., Lisec M., Millard R., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172 (2004) 1919
19. Haab F., Cardozo L., Chapple C., et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 47 (2005) 376
20. Kay G.G., Abou-Donia M.B., Messer Jr. W.S., et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 53 (2005) 2195
21. Wesnes K., Edgar C., Tretter R., et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 8 (2009) 615
22. Kay G., Crook T., Rekeda L., et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50 (2006) 317
23. Katz I.R., Sands L.P., Bilker W., et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 46 (1998) 8
24. Harewood G.C. From major to minor: are all endoscopic complications created equal?. Gastrointest Endosc 57 (2003) 141
25. Braunholtz D.A., Edwards S.J., and Lilford R.J. Are randomized clinical trials good for us (in the short term)?. Evidence for a "trial effect.". J Clin Epidemiol 54 (2001) 217
26. Garely A.D., Kaufman J.M., Sand P.K., et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 28 (2006) 1935
27. Samuels T.A., Mitcheson H.D., Vardy M.D., et al. Solifenacin significantly improves overactive bladder (OAB) symptoms, symptom-associated bother and other patient-reported outcomes: results from VIBRANT, a large, double-blind, placebo-controlled trial. Eur Urol 8 suppl. (2009) 168 abstract 190